The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.
| Gary Kelloff, M.D., NIH/NCI, (Co-Chair)
Emmett Schmidt, M.D., Ph.D., Merck (Co-Chair) Alex Snyder, Ph.D., Generate Biomedicines (SITC) (Co-Chair) Alexandre Akoulitchev, Ph.D., Oxford Biodynamics Jeff Allen, Ph.D., Friends of Cancer Research J. Carl Barrett, Ph.D., University of North Carolina Anna Berdine, M.S., Alamar Biosciences, Inc. Michelle Berny-Lang, Ph.D., NCI Donald A. Berry, Ph.D., MD Anderson Cancer Center Vikram Bhadrasain, M.D., NCI Gary Borzillo, Ph.D., Janssen Trixia Camacho, PharmD, BMS Claudio Carini, Ph.D., Kings College London Ronald Cheung, Jazz Pharmaceuticals Hearn Jay Cho, M.D., Ph.D., The Multiple Myeloma Research Foundation Steven Cole, NCI Cecile Combeau, Ph.D., Sanofi Adam Corner, BioRad Ed Driggers, Ph.D., General Metabolics Michael Espey, Ph.D., NCI Fennessy, Fiona M., PhD, MBBCH, RSNA Ida Grundberg, Ph.D., Olink Justin Guinney, Ph.D., Tempus Stanley R. Hamilton, M.D., City of Hope National Medical Center Sean Hanlon, Ph.D., NCI Lyndsay Harris, M.D., NCI Stephanie Hennek, Ph.D., PathAI Brandon Higgs, Ph.D., Genmab US, Inc. Steffan Ho, M.D., Ph.D., Pfizer Rob Iannone, M.D., Jazz Pharmaceuticals Peter Intile, SITC Donald Jackson, Ph.D., Sanofi Taylor Jensen, Ph.D., LabCorp John Jessup, M.D., Institute for Bioscience and Biotechnology Research Morten Karsdal, Ph.D., Nordic Bioscience |
Ilan (Lanny) Kirsch, M.D., Adaptive Biotechnologies
Jessica Kuzma, Ph.D., Standard Biotools Laura Lasiter. Ph.D., AstraZeneca Robert McCormack, Ph.D.,Janssen Doug Mirsky, Ph.D., Digital Medicine Society Achim Moesta, Ph.D., Regeneron Andrea Mortera, Empatica Veerendra Munugalavadla, Ph.D., AstraZeneca Larry Nagahara, Ph.D., John’s Hopkins University Michael O’Neal, M.D., Clario Geoff Oxnard, M.D., Eli Lily & Company Snehal Patel, Ph.D., Association for Molecular Pathology Reena Philip, Ph.D., FDA/OCE Vladimir Popov, Ph.D., FNLCR/NCI Scott Knowles Pruitt, M.D., Ph.D., Merck Anita Reddy, Ph.D., Amgen Michael Reeder, Ph.D., Johnson & Johnson Henry Rodriguez, Ph.D., NIH/NCI Vanessa Rodrik-Outmezguine, Ph.D., Eli Lilly & Company Marijana Rucevic, Ph.D., Olink Proteomics Mert Sahin, Ph.D., Durin Technologies Lawrence Schwartz, M.D., Memorial Sloan Kettering Maggie Scully, Ph.D.,Frederick Natl. Lab. For Cancer Research Howard Spiegel, Olink Proteomic Funda Suer, Ph.D., Durin Life Sciences Magadelena Thurin, Ph.D., NIH/NCI Peter Ujhazy, M.D., Ph.D., NIH/NCI Tamar Uziel, Ph.D., AbbVie Sarah Valentine, Digital Medicine Society Megann Vaughn, M.B.A., LabCorp Jian Wang, Ph.D., AstraZeneca Joel Wommack, Ph.D., Standard Biotools Rebekah Zinn, Ph.D., FDA |